SEC61G is altered in 0.37% of all cancers with lung adenocarcinoma, glioblastoma, conventional glioblastoma multiforme, non-small cell lung carcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations .
The most common alteration in SEC61G is SEC61G-EGFR Fusion (0.37%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.